- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00651183
Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Kontakter og lokationer
Studiesteder
-
-
-
Amstetten, Østrig
- Boehringer Ingelheim Investigational Site
-
Bad Hall, Østrig
- Boehringer Ingelheim Investigational Site
-
Bad Ischl, Østrig
- Boehringer Ingelheim Investigational Site
-
Bad Radkersburg, Østrig
- Boehringer Ingelheim Investigational Site
-
Baden, Østrig
- Boehringer Ingelheim Investigational Site
-
Bregenz, Østrig
- Boehringer Ingelheim Investigational Site
-
Bruck an der Mur, Østrig
- Boehringer Ingelheim Investigational Site
-
Deutschlandsberg, Østrig
- Boehringer Ingelheim Investigational Site
-
Dornbirn, Østrig
- Boehringer Ingelheim Investigational Site
-
Eisenstadt, Østrig
- Boehringer Ingelheim Investigational Site
-
Feldkirch, Østrig
- Boehringer Ingelheim Investigational Site
-
Feldkirchen, Østrig
- Boehringer Ingelheim Investigational Site
-
Gmunden, Østrig
- Boehringer Ingelheim Investigational Site
-
Graz, Østrig
- Boehringer Ingelheim Investigational Site
-
Grieskirchen, Østrig
- Boehringer Ingelheim Investigational Site
-
Gänserndorf, Østrig
- Boehringer Ingelheim Investigational Site
-
Hall in Tirol, Østrig
- Boehringer Ingelheim Investigational Site
-
Hallein, Østrig
- Boehringer Ingelheim Investigational Site
-
Hermagor, Østrig
- Boehringer Ingelheim Investigational Site
-
Hohenems, Østrig
- Boehringer Ingelheim Investigational Site
-
Hollabrunn, Østrig
- Boehringer Ingelheim Investigational Site
-
Horn, Østrig
- Boehringer Ingelheim Investigational Site
-
Imst, Østrig
- Boehringer Ingelheim Investigational Site
-
Innsbruck, Østrig
- Boehringer Ingelheim Investigational Site
-
Judenburg, Østrig
- Boehringer Ingelheim Investigational Site
-
Kapfenberg, Østrig
- Boehringer Ingelheim Investigational Site
-
Klagenfurt, Østrig
- Boehringer Ingelheim Investigational Site
-
Klosterneuburg, Østrig
- Boehringer Ingelheim Investigational Site
-
Knittelfeld, Østrig
- Boehringer Ingelheim Investigational Site
-
Krems, Østrig
- Boehringer Ingelheim Investigational Site
-
Kufstein, Østrig
- Boehringer Ingelheim Investigational Site
-
Leoben, Østrig
- Boehringer Ingelheim Investigational Site
-
Lienz, Østrig
- Boehringer Ingelheim Investigational Site
-
Lilienfeld, Østrig
- Boehringer Ingelheim Investigational Site
-
Linz, Østrig
- Boehringer Ingelheim Investigational Site
-
Melk, Østrig
- Boehringer Ingelheim Investigational Site
-
Neunkirchen, Østrig
- Boehringer Ingelheim Investigational Site
-
Oberwart, Østrig
- Boehringer Ingelheim Investigational Site
-
Ried im Innkreis, Østrig
- Boehringer Ingelheim Investigational Site
-
Salzburg, Østrig
- Boehringer Ingelheim Investigational Site
-
Scheibbs, Østrig
- Boehringer Ingelheim Investigational Site
-
Schwechat, Østrig
- Boehringer Ingelheim Investigational Site
-
Spital an der Drau, Østrig
- Boehringer Ingelheim Investigational Site
-
St. Johann im Pongau, Østrig
- Boehringer Ingelheim Investigational Site
-
St. Pölten, Østrig
- Boehringer Ingelheim Investigational Site
-
St. Veit an der Glan, Østrig
- Boehringer Ingelheim Investigational Site
-
Stegersbach, Østrig
- Boehringer Ingelheim Investigational Site
-
Stockerau, Østrig
- Boehringer Ingelheim Investigational Site
-
Telfs, Østrig
- Boehringer Ingelheim Investigational Site
-
Traun, Østrig
- Boehringer Ingelheim Investigational Site
-
Villach, Østrig
- Boehringer Ingelheim Investigational Site
-
Vöcklabruck, Østrig
- Boehringer Ingelheim Investigational Site
-
W. Neustadt, Østrig
- Boehringer Ingelheim Investigational Site
-
Wels, Østrig
- Boehringer Ingelheim Investigational Site
-
Wien, Østrig
- Boehringer Ingelheim Investigational Site
-
Wolfsberg, Østrig
- Boehringer Ingelheim Investigational Site
-
Wörgl, Østrig
- Boehringer Ingelheim Investigational Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Idiopathic PD with or without fluctuations
- Indication for treatment with Pramipexole
- Presence of at least mild depressive symptoms (as judged by the treating physician)
- Ability to reliably complete a self-rating scale (Hospital Anxiety and Depression Scale (HADS))
Exclusion Criteria:
- Any contraindications according to the Summary of Product Characteristics (SPC), hypersensitivity to pramipexole or to any of the excipients
- Ongoing treatment with pramipexole
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part I (Mentation, Behaviour and Mood)
Tidsramme: Baseline and Final (visit 3) - Change from baseline (i.e. decrease of score)
|
Rating scale scored from 0 (none) - 4 (severe). The UPDRS Part I (Mentation, Behaviour and Mood during the Past Week) consist of 4 items, each of them is scored from 0 (normal) to 4 (severe). Reduction in this score over time is interpreted as improvement. Total UPDRS part I score ranges from 0 = best score to 16 = worst score |
Baseline and Final (visit 3) - Change from baseline (i.e. decrease of score)
|
|
Change From Baseline in Hospital Anxiety and Depression Scale - HADS-D Depression Subscore
Tidsramme: Baseline and Final (visit 3) - Change from baseline (i.e. decrease of score)
|
Depression Scale - 7 items scored for each individual question from 0 = best and 3 = worst. HADS is a self-assessment scale for the symptom severity of anxiety disorders and depression. It comprises of 14 items, thereof seven statements describe anxiety and seven statements depression. Each answer is rated on a four-point scale (0-3). All seven answers are summarized and calculated to a total score to the anxiety scale and to the depression scale with a maximum score of 21 points for each scale. |
Baseline and Final (visit 3) - Change from baseline (i.e. decrease of score)
|
|
Change From Baseline in Hospital Anxiety and Depression Scale - HADS-A Anxiety Subscore
Tidsramme: Baseline and Final (visit 3) - Change from baseline (i.e. decrease of score)
|
Anxiety Scale - 7 items scored for each individual question from 0 = best and 3 = worst. HADS is a self-assessment scale for the symptom severity of anxiety disorders and depression. It comprises of 14 items, thereof seven statements describe anxiety and seven statements depression. Each answer is rated on a four-point scale (0-3). All seven answers are summarized and calculated to a total score to the anxiety scale and to the depression scale with a maximum score of 21 points for each scale. |
Baseline and Final (visit 3) - Change from baseline (i.e. decrease of score)
|
|
Change From Baseline in UPDRS Part III (Motor Examination)
Tidsramme: Baseline and Final (visit 3) - Change from baseline (i.e. decrease of score)
|
14 components rating scale with 27 items scored by 0 (none) - 4 (severe)
|
Baseline and Final (visit 3) - Change from baseline (i.e. decrease of score)
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Adfærdsmæssige symptomer
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Parkinsonlidelser
- Basal Ganglia Sygdomme
- Bevægelsesforstyrrelser
- Synukleinopatier
- Neurodegenerative sygdomme
- Depression
- Parkinsons sygdom
- Lægemidlers fysiologiske virkninger
- Neurotransmittermidler
- Molekylære mekanismer for farmakologisk virkning
- Beskyttelsesagenter
- Dopaminagonister
- Dopaminmidler
- Antioxidanter
- Antiparkinson-midler
- Midler mod dyskinesi
- Pramipexol
Andre undersøgelses-id-numre
- 248.649
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .